Zim Laboratories Ltd (NSE:ZIMLAB)

₹ 119.27 +2.68 (+2.3%) Market Cap: 5.81 Bil Enterprise Value: 6.96 Bil PE Ratio: 47.88 PB Ratio: 2.32 GF Score: 49/100

Q4 2025 ZIM Laboratories Ltd Earnings Call Transcript
May 22, 2025

₹91.53 (+3.39%)

Earnings

Q4 2025 ZIM Laboratories Ltd Earnings Call Transcript

May 22, 2025 / 06:30 AM GMT

Release Date Price: ₹91.53 (+3.39%)

Transcript

Key Points

Positve

Zim Laboratories Ltd (BOM:541400) reported a total operating income of INR 1,087 million for Q4 FY25, reflecting a 12.9% increase on a quarter-to-quarter basis.
The company's pharmaceutical segment contributed 75% of the total revenue, indicating a strong performance in its core business.
Export markets accounted for 83% of the total revenue, showcasing the company's successful international expansion.
The innovation-led segments, including new innovative products, contributed significantly to revenue, accounting for 16.5% of total revenue.
Zim Laboratories Ltd (BOM:541400) completed key strategic capital projects, including a dedicated neurology suite and a specialized liquid and pellet technology suite, enhancing its infrastructure and innovation capabilities.

Negative

Despite the growth in innovative segments, the company's overall margins have not shown significant improvement, with EBITA margin only slightly increasing from 11% to 12%.
The company faced a 7.7% decline in total operating income on a year-to-year basis for Q4 FY25.
There was a 39.7% decline in profit after tax compared to Q4 FY24, indicating challenges in maintaining profitability.
The domestic market revenue declined from INR 64.6 crores in FY24 to INR 53.6 crores in FY25, partly due to voluntary reduction in low-margin business and market headwinds.
The finance cost increased to INR 114 million, up from INR 69 million last year, primarily due to increased borrowing, impacting the company's financial health.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZIML.NS - Zim Laboratories Ltd
Q4 2025 ZIM Laboratories Ltd Earnings Call
May 22, 2025 / 06:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Zim Laboratories Limited Q4 and F 525 awnings conference call hosted by Go India advisors. As a reminder, all participant line will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing start and 0 on your touchdown phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Depika Sharma from Gondia advisors.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.